Pagano L, Valentini C G, Fianchi L, Caira M
Istituto di Ematologia, Università Cattolica del Sacro Cuore, Rome, Italy.
J Chemother. 2011 Feb;23(1):5-8. doi: 10.1179/joc.2011.23.1.5.
The proportion of patients with cancers who develop invasive fungal infections has increased dramatically over the past few decades. Most of these infections are diagnosed in patients with hematological malignancies, mainly in patients with acute myeloid leukemia and those undergoing allogeneic hematopoietic stem cell transplantation. For years deoxycolate amphotericin B has been considered the drug of choice for the treatment of invasive aspergillosis, but it has been outclassed by its lipid formulations and new triazoles (i.e. voriconazole), that produced better response rates; nonetheless recovery from neutropenia remains the most important factor influencing outcome.
在过去几十年中，罹患侵袭性真菌感染的癌症患者比例急剧上升。这些感染大多在血液系统恶性肿瘤患者中被诊断出来，主要是急性髓系白血病患者以及接受异基因造血干细胞移植的患者。多年来，脱氧胆酸盐两性霉素B一直被视为治疗侵袭性曲霉病的首选药物，但它已被脂质制剂和新型三唑类药物（即伏立康唑）超越，后者产生了更高的缓解率；尽管如此，从中性粒细胞减少症中恢复仍然是影响治疗结果的最重要因素。
